Influence of metabolic syndrome on risk stratification in hypertensive patients: differences between 2003 and 2007 ESH-ESC guidelines.
OBJECTIVE
To investigate the influence of metabolic syndrome (MS) on risk stratification and ulterior classification in hypertensive patients at entry into a hypertension unit by comparing the criteria of ESH-ESC 2003 and 2007 guidelines.


METHODS
720 consecutive patients attending a hospital-located hypertension unit were included in the study. They were classified with or without MS according to the ATP-III 2005 report. Patients underwent repeated office BP measurements and routine blood/urine examinations. In addition ultrasensitive CRP (uCRP), echocardiogram, fasting insulin, urinary albumin excretion were determined and HOMA index was calculated.


RESULTS
The prevalence of MS was 58.8 %. Abdominal obesity and fasting glucose were the most prevalent components of MS, and HDL-cholesterol the least prevalent. MS group had higher levels of LDL-cholesterol and higher prevalence of left ventricular hypertrophy and microalbuminuria. Patients with MS also presented a significant elevation in uCRP, fasting insulin and HOMA. BP was controlled in 55.6%. When we applied the 2003 guideline, 48.9% patients showed a high or very high added cardiovascular risk. With the applications of the 2007 guide the prevalence of this two categories reach 73.9%.


CONCLUSIONS
A significant difference in the risk pattern distribution is found when MS is considered in risk stratification in our hypertensive population. The accompanying increase in the levels of other cardiovascular risk factors and in the prevalence of target organ damage justifies the global intervention on cardiovascular risk recommended by 2007 ESH-ESC guidelines.
Martell
Nieves
N
H Clínico San Carlos - Hypertension Unit, Madrid, Spain. nmartellc@terra.es
Alvarez-Alvarez
Beatriz
B
Fernandez-Cruz
Arturo
A
D050153:Abdominal Fat / Q000503:physiopathology; D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000503:physiopathology; D001786:Blood Glucose / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology*; D008078:Cholesterol, LDL / Q000097:blood; D003430:Cross-Sectional Studies; D005215:Fasting; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications*; D017379:Hypertrophy, Left Ventricular / Q000453:epidemiology; D007328:Insulin / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000503:physiopathology; D008875:Middle Aged; D009765:Obesity / Q000503:physiopathology; D017410:Practice Guidelines as Topic; D015995:Prevalence; D012307:Risk Factors
D001786:Blood Glucose; D008078:Cholesterol, LDL; D007328:Insulin; D002097:C-Reactive Protein